

Receipt



COPY OF FILING
ORIGINAL FILED

Dkt. 65021/JPW/FHB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michale J. Elliott, et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
For : METHODS OF PREVENTING OR TREATING THROMBOSIS
WITH TUMOR NECROSIS FACTOR ANTAGONISTS

1185 Avenue of the Americas
New York, New York 10036
January 14, 2002

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231-9999

RECEIVED
MAR 13 2002
TECH CENTER 1600/2900

Sir:

COMMUNICATION TO CORRECT ERROR IN FILING RECEIPT

This Communication is filed to request a corrected Filing Receipt in connection with the above-identified application. Upon receipt of the updated Filing Receipt for the subject application, a copy of which is included as **Exhibit A**, applicants' undersigned attorney noticed an error. Specifically, the title is incorrectly listed.

a corrected Filing Receipt should read as follows:

--Title

METHODS OF PREVENTING OR TREATING THROMBOSIS WITH TUMOR
NECROSIS FACTOR ANTAGONISTS--


Applicants : Michael J. Elliott, et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
Page 2

The correct title may be found in the Amendment B filed with the U.S. Patent and Trademark Office on July 6, 1998 in connection with the subject application. A copy of the Amendment B is attached hereto as **Exhibit B**. Accordingly, applicants request that a corrected filing receipt be issued.


No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Office of Initial Patent Examination Customer Service Center Washington D.C. 20231


John P. White
Reg. No. 28,678

1/14/02
Date


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



UNITED STATES PATENT AND TRADEMARK OFFICE


FILE COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

CONFIRMATION NO. 4297

SERIAL NUMBER 08/602,272	FILING DATE 02/16/1996 RULE	CLASS 424	GROUP ART UNIT 1642	ATTORNEY DOCKET NO. KIR96-01	
APPLICANTS MICHAEL J. ELLIOTT, LONDON, EN, UNITED KINGDOM; RAVINDER N. MAINI, LONDON, EN, UNITED KINGDOM; MARC FELDMANN, LONDON, EN, UNITED KINGDOM;					
** CONTINUING DATA ***** ** FOREIGN APPLICATIONS *****					
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 10/31/2001					
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged _____ Examiner's Signature Initials		STATE OR COUNTRY EN	SHEETS DRAWING 4	TOTAL CLAIMS 50	INDEPENDENT CLAIMS 4
ADDRESS JOHN P. WHITE, ESQ. COOPER & DUNHAM 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036					
TITLE Methods of preventing or treating thrombosis with tumor necrosis factor antagonists					
FILING FEE RECEIVED 2014	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		



COPYRIGHTS
ORIGINAL FILED

65.1


Page 1 of 2 JPL

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
08/602,272	02/16/1996	1642	2014	KIR96-04	4	50	4

JOHN P. WHITE, ESQ. COOPER & DUNHAM
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036



CONFIRMATION NO. 4297

CORRECTED FILING RECEIPT



OC000000007005033

Date Mailed: 10/31/2001

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

MICHAEL J. ELLIOTT, LONDON, EN, UNITED KINGDOM;
RAVINDER N. MAINI, LONDON, EN, UNITED KINGDOM;
MARC FELDMANN, LONDON, EN, UNITED KINGDOM;

RECEIVED

MAR 13 2002

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 10/31/2001

CPA filed on: 08/10/2001

Projected Publication Date: 02/07/2002

Non-Publication Request: No

Early Publication Request: No

Title

METHODS OF PREVENTING OR TREATING CARDIOVASCULAR, CEREBROVASCULAR
AND THROMBOTIC DISORDERS WITH TUMOR NECROSIS FACTOR ANTAGONISTS

Preliminary Class

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).